Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969303 · ClinicalTrials.gov registry record
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
A clinical trial of Diabetic Macular Edema and AMD - Age-Related Macular Degeneration, sponsored by Notal Vision.
- Completed
- Registry status
- 287
- Enrollment target
- 1
- Study location
NCT03969303 is a study of Diabetic Macular Edema and AMD - Age-Related Macular Degeneration that has completed, run by Notal Vision. The registered enrollment target is 287 participants, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03969303, a study of Diabetic Macular Edema and AMD - Age-Related Macular Degeneration, has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- 287 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary objective: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular Degeneration) patients. Secondary objectives: 1. To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in DME (Diabetic Macular Edema) patients. 2. To evaluate patient experience when self-operating the Notal-OCT V2.5.
Conditions Studied
Interventions
- DEVICE Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Study Locations (1)
Maryland
- Elman Retina Group, PA - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2018-10-20 |
| Est. Completion | 2019-10-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03969303
The ClinicalTrials.gov registry entry for NCT03969303 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,790-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (92% lower). The listed sponsor is Notal Vision, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5) is the first listed.
NCT03969303 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03969303 about?
NCT03969303 is a clinical study titled "NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients". Primary objective: To evaluate the level of agreement between the NOTAL-OCT V2.5 and a commercial OCT in the presence of fluid as identified in the OCT images, in the central 10 degrees of the macula in AMD (Age-related Macular Degeneration) patients. Secondary objectives: 1. To evaluate the leve...
What is the current status of trial NCT03969303?
This trial is currently completed. The enrollment target is 287 participants. The study started on 2018-10-20. Estimated completion is 2019-10-04.
What conditions does trial NCT03969303 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, AMD - Age-Related Macular Degeneration.
What interventions are being tested in trial NCT03969303?
The interventions under investigation include: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5) (DEVICE).
Who is sponsoring clinical trial NCT03969303?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03969303 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Explore more on PlainTrial
Diabetic Macular Edema
All registered trials for this condition
AMD - Age-Related Macular Degeneration
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.